宜明昂科-B高开近10% 预计下半年公布IMM2510联合化疗2期试验结果

DoNews
May 23

5月23日,宜明昂科-B早盘高开近10%,现报9.99港元。公司与Instil Bio共同发布IMM2510/AXN-2510临床试验更新及非小细胞肺癌(NSCLC)开发战略。预计2025年下半年分享II期临床试验初步安全性和有效性结果,客观响应率与竞争对手类似阶段数据相当。IMM2510是一种PD-L1和VEGF双特异性抗体,用于治疗多种实体肿瘤癌症,计划年底完成一线NSCLC患者II期临床入组...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10